Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1016/S1470-2045(19)30351-1

Type

Journal article

Journal

Lancet Oncol

Publication Date

07/2019

Volume

20

Pages

904 - 905

Keywords

Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Ipilimumab, Kidney Neoplasms, Neoplasm Staging, Nivolumab, Practice Guidelines as Topic, United Kingdom